Spread the love
Post Views: 22

Emyria Limited (Emyria or the Company), a data-backed drug development company, is excited to share this report on the Company’s activities for the quarter ending December 30, 2020.

Highlights:

  • Launched first drug development programs backed by Emyria Data and filed IP:

    • EMD-003, targeting mental health and;

    • EMD-004, targeting irritable bowel syndrome;

  • Welcomed TGA announcement rescheduling low-dose CBD to Schedule 3 medicine

  • Formed partnership with Mind Medicine Australia to develop an evidence-generating care model for psychedelic-assisted therapy

  • Formed partnership with Sapphire Medical, to obtain UK patient data

  • Launched observational study into Autism Spectrum Disorder (ASD) with Zelira

  • Continued to see increased patient demand for clinical services across quarter

  • Grew revenues – 200% increase between the Qtr end 30 June 20 and Sep 20

  • A continuation of exceeding $500k cash receipts in the Dec 20 quarter

  • Consistent gross operational expenditure since listing of $1.5m per quarter

  • Investment and potential of our R&D demonstrated by $950k R&D refund

  • Strengthened cash position with strategic placement from Sixty Two Capital

Emyria’s Managing Director, Dr Michael Winlo, said: “Emyria ends a challenging 2020 with a strong quarter full of highlights.  We have increasing demand from patients for our independent and personalised model of care at Emerald Clinics. This demand is fueling the growth of our proprietary data asset which is, in turn, improving care, creating strong IP for the Company and supporting our own drug development programs.  Our leading program EMD-003, which launched in the December quarter, is a cannabinoid-based medicine pursuing registration with the TGA to help tackle the growing global concern of mental health and, in particular, the symptoms of anxiety, depression and stress.  Secondly, we formed new partnerships that will expand our therapeutic options and breadth of patient data.  Finally, we end the year also in a strong cash position to pursue our drug development programs and with new strategic support.”